A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.

@article{Okugawa2000ANH,
  title={A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.},
  author={Toshiharu Okugawa and Yoshiaki Ikuta and Yoshiaki Takahashi and Hiroto Obata and Koji Tanida and Michiaki Watanabe and Shosuke Imai and Reiko Furugen and Yoichi Nagata and Nagayasu Toyoda and Hiroshi Shiku},
  journal={European journal of immunology},
  year={2000},
  volume={30 11},
  pages={3338-46}
}
A mouse HER2-derived peptide, HER2p63 (A) (TYLPANASL), can induce K(d)-restricted mouse cytotoxic T lymphocytes (CTL) and also function as a tumor rejection antigen in an in vivo assay. Since the anchor motif of mouse K(d) for peptide binding has much similarity to that of human HLA-A2402, we asked if human HER2p63 (T) (TYLPTNASL) could induce HER2-specific CTL in HLA-A2402-positive individuals. Peripheral blood mononuclear cells (PBMC) of HLA-A2402-positive individuals were sensitized in vitro… CONTINUE READING